NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE was delisted on the 10th of May, 2024.
35 hedge funds and large institutions have $1.72M invested in NeuBase Therapeutics, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
3% more funds holding
Funds holding: 34 → 35 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
12% less capital invested
Capital invested by funds: $1.94M → $1.72M (-$226K)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$9.38K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$8.75K |
| 3 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
+$7.73K |
| 4 |
Jane Street
New York
|
+$2.39K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$1.26K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$131K |
| 2 |
CM
CM Management
Gulf Breeze,
Florida
|
-$53.1K |
| 3 |
Renaissance Technologies
New York
|
-$26K |
| 4 |
E
Ergoteles
New York
|
-$7.21K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$4.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
First Manhattan
New York
| $2.61K | – | – | – |
|
|
WP
27
WealthSource Partners
San Luis Obispo,
California
| $2.59K | – | – | – |
|
|
28
Jane Street
New York
| $1.91K | +$2.39K | +517 | New |
|
29
UBS Group
Zurich,
Switzerland
| $689 | +$859 | +186 | New |
|
30
Wells Fargo
San Francisco,
California
| $229 | -$919 | -199 | -76% |
|
31
Osaic Holdings
Scottsdale,
Arizona
| $83 | – | – | – |
|
32
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $79 | – | – | – |
|
|
NFSG
33
Newbridge Financial Services Group
Boca Raton,
Florida
| $46 | – | – | – |
|
34
Morgan Stanley
New York
| $28 | -$5 | -1 | -11% |
|
|
RDFA
35
Ritter Daniher Financial Advisory
Cincinnati,
Ohio
| $1 | – | – | – |
|
|
E
36
Ergoteles
New York
| – | -$7.21K | -1,895 | Closed |
|
|
HF
37
HRT Financial
New York
| – | -$2K | -779 | Closed |
|
38
Simplex Trading
Chicago,
Illinois
| – | +$397 | +86 | New |
|
NBSE Hedge Fund Activity: Q1 2023 in Review
35 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q1 2023, worth a combined $1.72M — down 12% from $1.94M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new NBSE positions and 3 closed out — a net gain of 1 holder — while 5 added to existing stakes and 7 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $9.38K. The largest seller was Vanguard Group, cutting an estimated $131K.
- 35 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q1 2023, up from 34 in Q4 2022.
- Funds reported $1.72M of NeuBase Therapeutics, Inc. Common Stock stock for Q1 2023, down 12% quarter-over-quarter.
- 4 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q1 2023 and 3 closed out, a net change of +1 holder.
- The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q1 2023 was Virtu Financial, an estimated $9.38K added.
- The largest NeuBase Therapeutics, Inc. Common Stock seller in Q1 2023 was Vanguard Group, an estimated $131K sold.
Based on aggregated 13F filings for Q1 2023.